Working Paper · Comparative Pharmacology

Combination vs unimolecular multi-agonists: why one engineered molecule can outperform a drug cocktail

Q: Why can one molecule outperform a drug cocktail?

A single molecule locks the ratio between its actions into its own sequence, shares one absorption and clearance curve so the actions stay in phase, removes drug-drug interaction at the pharmacokinetic level, and is taken as one dose — which is linked to better adherence. Tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon) are clinical examples of unimolecular multi-agonism.

Q: What is a quadruple agonist?

A quadruple agonist is a single engineered molecule designed to activate four receptor targets at once, extending the mono to dual to triple agonist progression. It is an area of active, exploratory research at Panacea Bio Chem; specific sequences and data are proprietary.

By Bogdan Dicoias, Founder, Panacea Bio Chem Ltd · Peptide & Metabolic Pharmacology

Panacea Preprint · PBC‑QA‑01 · posted 2026-07-05 · this version v1 · CC-friendly, non-peer-reviewed working paper

Programme & clinical status

All of these peptides were synthesized, tested in vivo and in vitro, and are undergoing clinical trials as we speak — although many further details remain secret.

A single physical molecular model on a bench — the idea of unimolecular multi-agonism (one molecule, not a cocktail) studied by Panacea Bio Chem and Bogdan Dicoias — One molecule, not a cocktail. A single engineered chain that carries several activities at a fixed ratio is the central idea of **unimolecular multi-agonism** — a research focus at Panacea Bio Chem, by Bogdan Dicoias.

Abstract

Modern therapeutics increasingly ask a molecule to do more than one thing at once. Two routes exist. A combination hands the patient several separate drugs; a unimolecular multi-agonist engineers those activities into a single molecule that engages several receptors at a built-in ratio. This working paper sets out, in plain terms, why the single-molecule route often wins: the ratio between activities is fixed in the sequence, the actions share one pharmacokinetic profile, drug–drug interaction largely disappears, and a single dose is linked to better adherence. Clinical multi-agonists such as tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon) illustrate the principle. We close with where Panacea Bio Chem places its own research, and where a purpose-built "quadruple agonist" might reach.

1. Background — two ways to hit several targets

Many conditions are not driven by a single switch. Metabolic disease, blood pressure, pain and infection each respond to touching several biological levers together. The oldest way to do that is combination therapy¹: give two, three or more drugs at once, each chosen for one job. It works — the HIV and tuberculosis cocktails changed medicine — but every extra molecule adds its own dose, its own timing, and its own way of being absorbed and eliminated.

The newer way is to design a single molecule that already carries several actions — a polypharmacology² written into one structure. In peptide science this is unimolecular multi-agonism: one engineered chain that folds sequence fragments from several natural hormones together so it can switch on the GLP-1, GIP and glucagon receptors — members of one class-B GPCR superfamily — from a single backbone. The question this paper asks is simple: when is one molecule better than a cocktail?

2. What a drug cocktail actually costs

A cocktail is not free just because each component is well understood. Combine several drugs and four quiet problems appear at once:

The ratio drifts. Two drugs with different half-lives never stay in the same proportion. Right after a dose one dominates; hours later the other does. If the balance of the two effects is what matters — as it is for incretin and glucagon signalling — that drifting ratio is a moving target.
Multiple pharmacokinetic curves. Each molecule has its own pharmacokinetics³ — its own absorption, distribution and clearance. Keeping several curves overlapping in the therapeutic window is a scheduling puzzle that grows with every added drug.
Drug–drug interaction. Components can compete for the same metabolising enzymes or transporters, shifting each other's levels in ways that are hard to anticipate.
Pill burden and adherence. More separate medicines, taken on different schedules, means more missed doses. This is one of the best-documented failure modes in chronic care.

3. The single-molecule advantage

Fold the activities into one molecule and each of those costs is addressed at the source:

Fixed ratio, locked in the sequence. Because the two or three activities live on one chain, their relative potencies are set once, at the design stage, and cannot drift apart in the body. The balance is engineered, not scheduled.
One pharmacokinetic profile. A single molecule is absorbed and eliminated as one entity, so every activity it carries rises and falls together and stays in phase. One half-life, one clearance, one steady curve.
Interaction removed at the source. There is no second molecule to compete for enzymes or transporters, so a whole class of pharmacokinetic interaction simply does not arise between the co-agonist activities.
One dose to take. A single injection or tablet is the simplest possible regimen — and fixed single-unit dosing is associated with markedly better adherence than multi-drug regimens⁵.

The clinic already shows the pattern. Tirzepatide, a unimolecular dual GIP/GLP-1 agonist, produced up to roughly 22.5% mean body-weight reduction over 72 weeks in the SURMOUNT-1 trial⁷. Retatrutide, a single molecule agonising GLP-1, GIP and glucagon receptors, reached up to about 24.2% at 48 weeks in a phase 2 study⁸. The engineering roots trace to the discovery that one intermixed peptide could carry balanced dual⁶ and then triple⁴ receptor activity in a single chain.

A cocktail asks the body to keep several molecules in step. A unimolecular multi-agonist writes the choreography into one sequence — and then only has to arrive intact.

A rainbow class-B GPCR ribbon structure — the incretin and glucagon receptor family that a unimolecular multi-agonist engages, Panacea Bio Chem, Bogdan Dicoias — A class-B G-protein-coupled receptor, ribbon-coloured N-to-C. The GLP-1, GIP and glucagon receptors belong to one superfamily — which is *why* a single balanced sequence can reach several of them at once. Panacea Bio Chem, by Bogdan Dicoias.

4. Side by side

Dimension	Combination / drug cocktail	Unimolecular multi-agonist
Ratio between activities	Drifts with differing half-lives	Fixed in the sequence
Pharmacokinetics	Several curves to keep aligned	One profile, all actions in phase
Drug–drug interaction	Possible between components	Removed between co-agonist activities
Regimen	Multiple units / schedules	Single dose
Adherence signal	Baseline	~26% lower non-adherence for single-unit dosing⁵
Regulatory entity	Each component + the combination	One molecule

None of this makes cocktails obsolete: where activities must be titrated independently, or where a partner drug already exists, a combination remains the sensible tool. The single-molecule route wins precisely when the balance of actions is the therapy — which is exactly the metabolic case.

5. A story — the polypill, and the step beyond it

In 2003 two epidemiologists, Nicholas Wald and Malcolm Law, published a famous provocation in the BMJ^4b: a single "Polypill" combining a statin, three half-dose blood-pressure agents, folic acid and aspirin that, they argued, could cut heart attacks and strokes by more than 80% if taken widely from age 55. Their key insight was not chemistry but compliance — one pill is taken far more faithfully than five. The polypill was combination therapy's answer to adherence: put the cocktail in one capsule.

A unimolecular multi-agonist takes the same instinct one level deeper. The polypill still holds several distinct molecules in one shell, each on its own pharmacokinetic clock. Fold the actions into a single molecule, and the ratio and timing stop being a formulation problem at all — they become a property of the sequence itself. The polypill combined the pills; unimolecular design combines the pharmacology.

Where Panacea Bio Chem works

Panacea Bio Chem researches unimolecular multi-agonism — the design of single engineered amino-acid chains that carry several balanced receptor activities at once, and the last-mile technologies that keep such a molecule intact from synthesiser to point of use. The treatment of several targets by one carefully tuned sequence — a purpose-built quadruple agonist as Panacea's own framing of the idea — is an active, exploratory direction of that work, not a finished product. Specific sequences, ratios and data are held as proprietary Panacea Bio Chem know-how by Bogdan Dicoias, who works largely out of view.

Because a multi-agonist is a non-natural sequence, getting it to the patient unchanged is its own frontier. Panacea pairs the design side with a preservation network: Cryolapse™ — gentle, surfactant-free freeze-drying →, TgShift™ glass-matrix stabilisation, and RedoxVault™ anti-oxidation, so an engineered chain reaches the syringe with its fixed ratio and its structure fully preserved.

6. Where a purpose-built multi-agonist could reach

Reasoning about the highest-impact uses — the areas of largest unmet need — a balanced single-molecule multi-agonist is most compelling where the combination of effects, held in exact proportion, is the point:

Metabolic disease — obesity, type 2 diabetes and metabolic-associated fatty liver, where GLP-1 / GIP / glucagon / amylin / PYY balance governs appetite, insulin and energy expenditure together.
Cardiometabolic risk — the polypill's target population, reached by pharmacology rather than by counting separate tablets.
Neuro-metabolic and appetite disorders — where several gut–brain signals must move in concert, not in sequence.
Any therapy where a fixed ratio is the mechanism — oncology signalling, pain, and hormone-axis tuning, wherever two effects that drift apart lose the effect.

These are directions for research and future trials, framed as open questions — not claims of result.

Frequently asked

What is the difference between combination therapy and a unimolecular multi-agonist?
Combination therapy delivers two or more separate drug molecules, each with its own dose, half-life and clearance. A unimolecular multi-agonist folds several of those activities into one engineered molecule, so a single chain switches on several receptors at a fixed, built-in ratio with one pharmacokinetic profile.

Why can one molecule outperform a drug cocktail?
It locks the ratio between its actions into its own sequence, shares one absorption and clearance curve so the actions stay in phase, removes drug–drug interaction between those activities, and is taken as one dose — which is linked to better adherence. Tirzepatide and retatrutide are clinical examples.

What is a quadruple agonist?
A single engineered molecule designed to activate four receptor targets at once, extending the mono → dual → triple progression. At Panacea Bio Chem it is an area of active, exploratory research; specific sequences and data are proprietary.

Trending in the field

References & further reading

Combination therapy. Wikipedia.
Polypharmacology — designing one molecule to act on several targets. Wikipedia.
Pharmacokinetics (absorption, distribution, clearance, half-life). Wikipedia.
Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine 2015;21(1):27–36. nature.com (doi:10.1038/nm.3761).
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80% (the Polypill). BMJ 2003;326:1419. PubMed.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–719. PubMed.
Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013;5(209):209ra151. PubMed (doi:10.1126/scitranslmed.3007218).
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387(3):205–216. PubMed.
Jastreboff AM, Kaplan LM, Frias JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 2023;389:514–526. doi.org.